Related references
Note: Only part of the references are listed.Sutimlimab in patients with cold agglutinin disease results of the randomized placebo-controlled phase 3 CADENZA trial
Alexander Roeth et al.
BLOOD (2022)
Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study
Bruno Fattizzo et al.
HAEMATOLOGICA (2021)
How I treat cold agglutinin disease
Sigbjorn Berentsen
BLOOD (2021)
The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease
Anna Zaninoni et al.
FRONTIERS IN IMMUNOLOGY (2021)
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sutimlimab in Cold Agglutinin Disease
Alexander Roeth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome
Marit Jalink et al.
BLOOD (2021)
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
Ulrich Jaeger et al.
BLOOD REVIEWS (2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients
Sigbjorn Berentsen et al.
BLOOD (2020)
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia
Sigbjorn Berentsen
FRONTIERS IN IMMUNOLOGY (2020)
C3inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Cold agglutinins: fending off the attack
Sigbjorn Berentsen
BLOOD (2019)
Primary and Secondary Immune Cytopenias Evaluation and Treatment Approach in Children
Taylor Olmsted Kim et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial
Ulrich Jaeger et al.
BLOOD (2019)
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro
Pavel A. Nikitin et al.
JOURNAL OF IMMUNOLOGY (2019)
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study
Giuseppe Rossi et al.
BLOOD (2018)
How I manage patients with cold agglutinin disease
Sigbjorn Berentsen
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease
Sigbjorn Berentsen
SEMINARS IN HEMATOLOGY (2018)
Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial
Alexander Roeth et al.
BLOOD ADVANCES (2018)
Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization
Megan Mullins et al.
BLOOD ADVANCES (2017)
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano et al.
BLOOD (2014)
Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma
Ulla Randen et al.
HAEMATOLOGICA (2014)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Diagnosis and Management of Autoimmune Cytopenias in Childhood
David T. Teachey et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2013)
Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia
Sigbjorn Berentsen et al.
BLOOD REVIEWS (2012)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
Sigbjorn Berentsen et al.
BLOOD (2010)
Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib
Kenneth R. Carson et al.
BLOOD (2010)
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice Evidence-Based Approach from the Apheresis Applications Committee of the American Society for Apheresis
Zbigniew M. Szczepiorkowski et al.
JOURNAL OF CLINICAL APHERESIS (2010)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rituximab in chronic cold agglutinin disease:: a prospective study of 20 patients
C Schöllkopf et al.
LEUKEMIA & LYMPHOMA (2006)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
S Berentsen et al.
BLOOD (2004)
Acute phase haemolysis in chronic cold agglutinin disease
E Ulvestad et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
Share Paper
